ArticleCancer imaging : the official publication of the International Cancer Imaging Society2014
The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparing the diagnostic efficacy of [Frontiers in medicine · 2025Pooled it
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Site-Specific Patterns of Distant Relapse on ^18F-FDG PET/Contrast-Enhanced CT According to Molecular Subtype in Breast Cancer: A Retrospective Cohort Study.Nuclear medicine and molecular imaging · 2026Article
- PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- Ipsilateral breast tumor recurrence after breast-conserving surgery: insights into biology and treatment.Breast cancer research and treatment · 2023Article
- Performance of [18F]FDG-PET/CT Imaging in First Recurrence of Invasive Lobular Carcinoma.Journal of clinical medicine · 2023Article
- Article
- Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer.Cancers · 2021Article
- Impact ofEuropean journal of radiology · 2020Article
- Prognostic Value of Dual-Time-PointDiagnostics (Basel, Switzerland) · 2020Article
- Comparison of diagnostic sensitivity of [EJNMMI research · 2020Article
- Novel nanomedicine with a chemical-exchange saturation transfer effect for breast cancer treatment in vivo.Journal of nanobiotechnology · 2019Article
- Reirradiation of recurrent breast cancer with proton beam therapy: A case report and literature review.World journal of clinical oncology · 2019Article
- The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer.Molecular imaging and biology · 2019Review
- Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.Nuclear medicine communications · 2019Article
- Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer.Nuclear medicine communications · 2016Article
- Present and future role of FDG-PET/CT imaging in the management of breast cancer.Japanese journal of radiology · 2016Review
- Positron Emission Tomography in Breast Cancer.Diagnostics (Basel, Switzerland) · 2015Review
- The diagnostic value of 18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis.BioMed research international · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incremental value of 18FDG PET/CT in patients with breast cancer (BC) compared to conventional imaging (CI) in clinical practice is unclear. The aim of this study was to evaluate the management impact and prognostic value of 18 F-FDG PET/CT in this setting.
methodsSixty-three patients who were referred to our institution for suspicion of BC relapse were retrospectively enrolled. All patients had been evaluated with CI and underwent PET/CT. At a median follow-up of 61 months, serial clinical, imaging and pathologic results were obtained to validate diagnostic findings. Overall Survival (OS) was estimated using Kaplan Meier methods and analyzed using the Cox proportional hazards regression models.
resultsForty-two patients had a confirmed relapse with 37 (88%) positive on CI and 40 (95%) positive on PET/CT. When compared with CI, PET/CT had a higher negative predictive value (86% versus 54%) and positive predictive value (95% versus 70%). The management impact of PET/CT was high (change of treatment modality or intent) in 30 patients (48%) and medium (change in radiation treatment volume or dose fractionation) in 6 patients (9%). Thirty-nine patients (62%) died during follow-up. The PET/CT result was a highly significant predictor of OS (Hazard Ratio [95% Confidence Interval] =4.7 [2.0-10.9] for PET positive versus PET negative for a systemic recurrence; p = 0.0003). In a Cox multivariate analysis including other prognosis factors, PET/CT findings predicted survival (p = 0.005). In contrast, restaging by CI was not significant predictor of survival.
conclusionOur study support the value of 18 F-FDG PET/CT in providing incremental information that influence patient management and refine prognostic stratification in the setting of suspected recurrent breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.